Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond - PubMed (original) (raw)

Review

. 2008 May:21 Suppl 2:S16-22.

doi: 10.1038/modpathol.3801018.

Affiliations

• PMID: 18437168
• DOI: 10.1038/modpathol.3801018

Free article

Review

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

Marc Ladanyi et al. Mod Pathol. 2008 May.

Free article

Abstract

Somatic mutations in certain tyrosine kinases have emerged as central 'drivers' of specific cancers and these mutant proteins are proving to be excellent substrates for targeted therapies. This is the case for mutant EGFR-dependent lung adenocarcinomas, where EGFR mutation testing is already being used to help guide treatment decisions. Here, we provide an overview of the biology of EGFR-targeted therapies and the clinical experience to date, the positive and negative predictors of response, pathologic correlates of EGFR-mutant status, testing methods to establish patient eligibility for these agents, and the basis for primary and secondary resistance.

PubMed Disclaimer

Similar articles

• Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
  Juchum M, Günther M, Laufer SA. Juchum M, et al. Drug Resist Updat. 2015 May;20:12-28. doi: 10.1016/j.drup.2015.05.002. Epub 2015 May 12. Drug Resist Updat. 2015. PMID: 26021435 Review.
• Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.
  Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, Ladanyi M. Yu HA, et al. JAMA Oncol. 2015 Oct;1(7):982-4. doi: 10.1001/jamaoncol.2015.1066. JAMA Oncol. 2015. PMID: 26181354 Free PMC article. No abstract available.
• Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
  Lindahl KH, Sørensen FB, Jonstrup SP, Olsen KE, Loeschke S. Lindahl KH, et al. APMIS. 2015 Apr;123(4):289-97. doi: 10.1111/apm.12350. Epub 2014 Dec 31. APMIS. 2015. PMID: 25556929
• Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
  Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X. Lin C, et al. Clin Lung Cancer. 2015 Sep;16(5):e25-35. doi: 10.1016/j.cllc.2015.02.002. Epub 2015 Feb 19. Clin Lung Cancer. 2015. PMID: 25801750
• Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
  Rybarczyk-Kasiuchnicz A, Ramlau R, Stencel K. Rybarczyk-Kasiuchnicz A, et al. Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593. Int J Mol Sci. 2021. PMID: 33435596 Free PMC article. Review.

Cited by

• EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.
  Antonicelli A, Cafarotti S, Indini A, Galli A, Russo A, Cesario A, Lococo FM, Russo P, Mainini AF, Bonifati LG, Nosotti M, Santambrogio L, Margaritora S, Granone PM, Dutly AE. Antonicelli A, et al. Int J Med Sci. 2013;10(3):320-30. doi: 10.7150/ijms.4609. Epub 2013 Feb 11. Int J Med Sci. 2013. PMID: 23423768 Free PMC article. Review.
• A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines.
  Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. Singleton KR, et al. Mol Pharmacol. 2013 Apr;83(4):882-93. doi: 10.1124/mol.112.084111. Epub 2013 Jan 31. Mol Pharmacol. 2013. PMID: 23371912 Free PMC article.
• High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma.
  Zhang J, Ni SS, Zhao WL, Dong XC, Wang JL. Zhang J, et al. Tumour Biol. 2013 Aug;34(4):2397-401. doi: 10.1007/s13277-013-0789-9. Epub 2013 Apr 18. Tumour Biol. 2013. PMID: 23595221
• The genomics of lung adenocarcinoma: opportunities for targeted therapies.
  Greulich H. Greulich H. Genes Cancer. 2010 Dec;1(12):1200-10. doi: 10.1177/1947601911407324. Genes Cancer. 2010. PMID: 21779443 Free PMC article.
• Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse.
  Mervai Z, Egedi K, Kovalszky I, Baghy K. Mervai Z, et al. BMC Cancer. 2018 Feb 7;18(1):157. doi: 10.1186/s12885-018-4068-4. BMC Cancer. 2018. PMID: 29415661 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal